NCT04256148View on ClinicalTrials.gov

ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2021

Primary Completion Date

October 30, 2022

Study Completion Date

April 30, 2023

Conditions
Warm Autoimmune Hemolytic Anemia
Interventions
BIOLOGICAL

ALXN1830

Administered via intravenous (IV) infusion

OTHER

Placebo

Matching placebo (sterile liquid diluent) administered via IV infusion

Trial Locations (1)

90602

Alexion Study Site, Whittier

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY